<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>For patients with inherited BM failure (BMF) or those with acquired BMF who fail immunosuppressive therapy and who lack a suitable alternative donor, the prognosis remains poor </plain></SENT>
<SENT sid="1" pm="."><plain>Umbilical cord blood transplantation has extended the availability of hematopoietic stem cell transplantation in the absence of a suitable donor </plain></SENT>
<SENT sid="2" pm="."><plain>A recent EBMT study confirmed the feasibility of this treatment and highlighted the fundamental role of the TNC dose (&gt;3.9 Ã— 10(7)/kg TNC/kg) on both engraftment and OS using cord blood as stem cell source in severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>However, this procedure is still experimental and should be evaluated only through prospective clinical trials </plain></SENT>
</text></document>